Bliss GVS Pharma Ltd (BLISSGVS) is currently trading at 648.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bliss GVS Pharma Limited is an integrated pharmaceutical manufacturer engaged in manufacturing, marketing, trading and export of formulations, operating multiple WHO‑GMP and USFDA‑approved facilities including sites at Palghar and Vevoor, and focused on contract manufacturing and regulated‑market exports for therapeutic formulations. The company reported a strong June 30, 2026 quarter with consolidated revenue of Rs. 28,557.56 lakh and standalone revenue of Rs. 22,158.51 lakh, representing year‑on‑year growth north of 35% and marked improvement in profitability, signalling recovery and faster sales conversion into earnings for Bliss GVS Pharma. Profitability expanded materially: standalone PBT of Rs. 5,120.92 lakh and consolidated PBT of Rs. 7,548.31 lakh produced elevated PBT margins above 23% and 26% respectively, showing operational leverage and better fixed‑cost absorption at Bliss GVS Pharma following capacity utilisation and sales mix improvement. Operational momentum is underpinned by regulatory milestones and manufacturing investments: USFDA approval for Palghar, commissioning of a semi‑solid plant, and expansion of suppositories/pessaries capacity, indicating Bliss GVS Pharma is transitioning from domestic focus to sustained growth in regulated export markets through targeted capex and partnerships.

Over the past 52 weeks, Bliss GVS Pharma Ltd has traded between a low of ₹118.35 and a high of ₹744.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bliss GVS Pharma Ltd has a market capitalization of approximately 7,260.71. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bliss GVS Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 43.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,260.71 Cr, Bliss GVS Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bliss GVS Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bliss GVS Pharma Ltd is 43.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Bliss GVS Pharma’s board is scheduled to consider and approve the September 2026 quarter and half-year results on October 29, 2026.

The company said control changed on September 28, 2026, when the acquirer group completed the transaction and became the promoters.

It said Anupam Rasayan India and its PAC acquired 5,09,84,595 shares (47.95%) on 28 September 2026, taking their combined holding to 50.07% and resulting in a change in control.

Post-acquisition, Anupam Rasayan and Mates Visa Consultancy Private Limited (PAC) together hold 5,32,36,264 shares, equal to 50.07% of Bliss GVS Pharma’s equity share capital.